Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec:68:104104.
doi: 10.1016/j.msard.2022.104104. Epub 2022 Aug 12.

Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM

Juan I Rojas  1 , Geraldine G Luetic  2 , Carlos Vrech  3 , Agustín Pappolla  4 , Liliana Patrucco  5 , Edgardo Cristiano  5 , Mariano Marrodan  6 , María C Ysrraelit  6 , Marcela Fiol  6 , Jorge Correale  6 , Leila Cohen  7 , Ricardo Alonso  8 , Berenice Silva  6 , Magdalena Casas  6 , Orlando Garcea  6 , Norma Deri  9 , Marcos Burgos  10 , Susana Liwacki  11 , Verónica Tkachuk  12 , Andres Barboza  13 , Raúl Piedrabuena  14 , Patricio Blaya  15 , Judith Steinberg  16 , Alejandra Martínez  17 , Adriana Carra  18 , Darío Tavolini  19 , Pablo López  20 , Eduardo Knorre  21 , Pedro Nofal  22 , Edgar Carnero Contentti  20 , Amelia Alves Pinheiro  23 , Felisa Leguizamon  21 , Emanuel Silva  24 , Javier Hryb  25 , María Eugenia Balbuena  12 , Gisela Zanga  26 , Matías Kohler  27 , Luciana Lazaro  7 , Santiago Tizio  28 , Carolina Mainella  29 , Jorge Blanche  30 , Marcela Parada Marcilla  31 , María Eugenia Fracaro  32 , María Laura Menichini  33 , Gustavo Sgrilli  34 , Pablo Divi  35 , Miguel Jacobo  35 , Mariela Cabrera  36 , Jimena Míguez  37 , Nora Fernandez Liguori  7 , Juan Pablo Viglione  38 , Debora Nadur  12 , Marina Alonso Serena  39 , Sebastián Nuñez  40
Affiliations

Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM

Juan I Rojas et al. Mult Scler Relat Disord. 2022 Dec.

Abstract

The objective of the study was to evaluate the incidence of COVID-19 after complete vaccination in people with multiple sclerosis (PwMS) included in the Argentinean MS and NMOSD registry (RelevarEM, NCT03375177).

Methods: cohort study conducted between May 2021 and December 2021. The primary outcome was the appearance of infection during the follow-up time (at least three months after complete vaccination (second dose)). Data was collected through the contact between the treating physician and the patient. Specific information was requested (date, symptoms, need for hospitalization, ventilatory assistance, treatment, and evolution). The contact was made every 30 days during the period of 3 months after the full dose vaccination. A positive COVID-19 case was defined according to the definition established by the Ministry of Health in Argentina. Cumulative incidence was reported by Kaplan Meier survival curves as well as incidence density.

Results: A total of 576 PwMS were included, mean age 45.2 ± 13 years, 432 (75%) RRMS, 403 (70%) were female. The mean and median time of follow-up after the second dose was 91 ± 17 and 94 ± 21 days respectively. Most frequent first and second dose received was Astra-Zeneca vaccine, followed by Sputnik V vaccine. During follow-up a total of twenty COVID-19 cases were observed for a total exposure time of 39,557 days. The overall cumulative incidence for the observed period was 3.4% (SE 0.4%) with an overall incidence density of 5 × 10.000 patients/day (95%CI 0.7-12). We observed more cases in woman than men with an incidence density of 6 × 10.000 patients/day (95%CI 0.9-9) vs. 3 × 10.000 patients/day (95%CI 0.2-6) respectively, but not significantly different (IRR 1.7 95% CI 0.56-7.37 p = 0.15).

Conclusion: we found an incidence density of breakthrough COVID-19 infection of 5 × 10.000 patients/day (95%CI 0.7-12) after vaccination in Argentina.

Keywords: Argentina; Breakthrough; COVID-19; Incidence; Multiple sclerosis; Vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Authors declare no potential conflicts of interest regarding this research, authorship and/or publication of this article. We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome

References

    1. Achiron A., Dolev M., Menascu S., Zohar D.N., Dreyer-Alster S., Miron S., Shirbint E., Magalashvili D., Flechter S., Givon U., Guber D., Stern Y., Polliack M., Falb R., Gurevich M. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult. Scler. 2021;27(6):864–870. - PMC - PubMed
    1. Alonso R., Chertcoff A., Leguizamon F.D.V., Galleguillos Goiry L., Eizaguirre M.B., Rodriguez R., Sosa M., Carballido S., Cruchet V., de Jong-Martis A., Giachello S., Henestroza P., Ferrandina F., Bauer J., Carra A., Silva B.A. Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. Mult. Scler. J. Exp. Transl. Clin. 2021;7(4) 20552173211061543. - PMC - PubMed
    1. Alonso R., Silva B., Garcea O., Diaz P.E.C., Dos Passos G.R., Navarro D.A.R., Valle L.A.G., Salinas L.C.R., Negrotto L., Luetic G., Tkachuk V.A., Miguez J., de Bedoya F.H.D., Goiry L.G., Sanchez N.E.R., Burgos M., Steinberg J., Balbuena M.E., Alvarez P.M., Lopez P.A., Ysrraelit M.C., Leon R.A., Cohen A.B., Gracia F., Molina O., Casas M., Deri N.H., Pappolla A., Patrucco L., Cristiano E., Tavolini D., Nadur D., Granda A.M.T., Weiser R., Cassara F.P., Sinay V., Rodriguez C.C., Lazaro L.G., Menichini M.L., Piedrabuena R., Escobar G.O., Carra A., Chertcoff A., Pujols B.S., Vrech C., Tarulla A., Carvajal R., Mainella C., Becker J., Peeters L.M., Walton C., Serena M.A., Nunez S., Rojas J.I. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM. Mult. Scler. Relat. Disord. 2021;51 - PMC - PubMed
    1. Belete T.M. Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect. Drug Resist. 2021;14:151–161. - PMC - PubMed
    1. Brill L., Rechtman A., Zveik O., Haham N., Oiknine-Djian E., Wolf D.G., Levin N., Raposo C., Vaknin-Dembinsky A. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2021;78(12):1510–1514. - PMC - PubMed

Supplementary concepts

Associated data